Respiratory Tract Viral Infection
Conditions
Keywords
respiratory tract infections, virus shedding, cancer, Immunocompromised Host
Brief summary
The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much studied in that population whereas it is probably longer than that in immunocompetent patients. Thereby it may be a source of transmission amongst these immunocompromised patients.
Detailed description
The development of multiplex polymerase chain reaction (PCR) tests has greatly improved the diagnosis of respiratory tract viral infections by increasing its sensitivity and the diversity of viral species detected. However, there are few data concerning respiratory tract viral infections amongst hematology and oncology patients. Especially, the duration of viral shedding following an infection has not been much studied whereas it is a source of inter-individual transmission between immunocompromised patients who are more likely to develop severe disease. Studies conducted so far concerned mainly hematology patients. They have shown that viral carriage could last up to one month and a half in some patients with hematological malignancy. The aim of this study is to determine the duration of the viral shedding in patients from hematology and oncology units after a respiratory tract viral infection for the ten main viruses involved in order to better manage these infections and to better prevent their transmission.
Interventions
DIAGNOSTIC_TESTnasal swabs
Iterative nasal swabs will be performed to screen for virus shedding
Sponsors
Poitiers University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Iterative nasal swabs will be performed to screen for virus shedding
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with solid organ cancer or haematological malignancy with or without chemotherapy * Having symptoms of upper and/or lower respiratory tract infection * Virus detected by PCR in nasal sample * Signature of consent
Exclusion criteria
* Hematological stem cell and solid organ recipients * No health insurance * protected people
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nasal carriage of virus after a viral respiratory tract infection | Up to 1 year | Iterative nasal swab to assess the duration of that carryiage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of viral coinfections | 2 years | — |
| Prevalence of bacterial coinfections | 2 years | — |
| transmission of respiratory tract viral infections by relatives | 2 years | with a survey filled by the patient |
| respiratory complications due to respiratory tract viral infections | 2 years | — |
| extra-pulmonary symptoms due to respiratory tract viral infections | 2 years | — |
| effect of influenza vaccine on viral shedding | 2 years | — |
| Prevalence of upper and lower respiratory tract infections | 2 years | — |
| nosocomial transmission of respiratory tract viral infection | 2 years | — |
| delay of chemotherapy due to respiratory infection | 2 years | — |
| survival after a respiratory tract viral infection | 30 days | — |
| TTV viral load as a marker of immunodepression in oncology and hematology patients | 2 years | TTV viral load at each visit |
| Correlation between TTV viral load and duration of viral shedding and severity of respiratory tract infection | 2 years | — |
| risk factors to do severe form of respiratory tract infection | 2 years | — |
Countries
France
Outcome results
None listed